Ronan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, Lucia Carril-Ajuria, Larissa Rainho, Natacha Naoun, Jean-Mehdi Jouniaux, Lisa Boselli, Marie Naigeon, Francois-Xavier Danlos, Bernard Escudier, Jean-Yves Scoazec, Lydie Cassard, Laurence Albiges, Nathalie Chaput
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets of patients and is now the standard of care in several solid tumor types. However, immunotherapy activity beyond conventional immune checkpoint inhibition is plateauing, and biomarkers are overall lacking to guide treatment selection. Most studies have focused on T cell engagement and response, but there is a growing evidence that B cells may be key players in the establishment of an organized immune response, notably through tertiary lymphoid structures...
April 16, 2024: Journal for Immunotherapy of Cancer